Zoledronic acid - Axsome Therapeutics

Drug Profile

Zoledronic acid - Axsome Therapeutics

Alternative Names: AXS 02; Oral zoledronate

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator ANTECIP BIOVENTURES
  • Developer Axsome Therapeutics
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Pain
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain

Most Recent Events

  • 01 Feb 2017 Axsome receives IND clearance from the US FDA for its phase III trial in Back pain (10-K, March 2017)
  • 14 Nov 2016 Axsome Therapeutics announces intention to submit IND for Back pain with US FDA by year end 2016
  • 04 Oct 2016 Pharmacodynamics data from a preclincial trial in Pain released by Axsome Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top